All In Biotech

Drug Trial Radar · NCT07072195

A Study of AMC6156 in People With Sarcopenia

A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of AMC6156 in Patients With Sarcopenia

Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Jul 1, 2025

Primary completion

Oct 31, 2026

Study completion Feb 15, 2027

Sponsor

Lead sponsor
Animuscure Inc.Industry
Sponsor type
Industry
First posted
Jul 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial aims to find out whether AMC6156 can improve physical function and is safe in older adults with sarcopenia. Participants will take AMC6156 or a placebo daily for 12 weeks, and their movement, strength, and safety will be regularly monitored through tests and checkups.

Conditions

  • Sarcopenia in Elderly
  • Sarcopenia

Interventions

  • AMC6156 0.1mgDrug

    Oral administration of AMC6156 in tablet form at a dose of 0.1 mg once daily for 12 weeks.

  • AMC6156 0.3mgDrug

    Oral administration of AMC6156 in tablet form at a dose of 0.3 mg once daily for 12 weeks.

  • AMC6156 1.0mgDrug

    Oral administration of AMC6156 in tablet form at a dose of 1.0 mg once daily for 12 weeks.

  • PlaceboDrug

    Oral administration of placebo tablets matching AMC6156 in appearance, once daily for 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Short Physical Performance Battery (SPPB) Score from Baseline to Week 12Time frame: At Visit 1 (Screening), Visit 2 (Week 0, Baseline), Visit 3 (Week 4), Visit 4 (Week 8), and Visit 5 (Week 12)

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • CHA Bundang Medical Center

    Seongnam-si, Gyeonggi-do, South Korea · Recruiting

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea · Recruiting

  • Ajou University Hospital

    Suwon, Gyeonggi-do, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.